Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Intuitive Surgical is a leader in the surgical robotics space, with a large installed base and strong recurring revenues.
Consumer sentiment is flashing recession warnings, yet three blue-chip dividend legends are quietly building cases for returns that would shock most defensive investors heading into 2027.
The yield you chase at 52 could quietly cannibalize the very nest egg you need at 62. Before you reach for the biggest monthly payout, understand the compounding trap hiding inside each income tier.
Chasing a $50,000 monthly dividend stream sounds like a math problem, but the yield you pick determines whether your portfolio funds four decades of freedom or quietly cannibalizes itself while the checks keep arriving.
A $1.25 million nest egg can fund a very different retirement depending on one number: your withdrawal yield. The gap between a conservative dividend portfolio and an aggressive one swings your annual income by tens of thousands of dollars, but the safer-looking choice does not always win.
Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company’s talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to other large...
HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.
Higher Darzalex and Kesimpta royalties supported a $195 million increase in Genmab's annual revenue-guidance midpoint.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Cooper Cos. could get a pop from the sale of a surgical unit. What two activists are up to in the stock.
The number that separates a comfortable retirement from a perpetual side hustle depends entirely on which yield tier you trust with your capital, and the answer surprises most income investors who assume bigger payouts always win.
Johnson and Johnson just committed over a billion dollars to flood the market with American-made contact lenses, but retirees banking on Medicare to share the cost are about to get a rude awakening at the pharmacy counter.
ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.
An 8% yield looks like a shortcut to $80,000 a year without selling a single share, but the brokerage account tells a different story than the headline number does.
Royalty Pharma PLC (RPRX) reports 14% total receipts growth and raises full-year 2026 guidance for the second consecutive quarter.
Compass Pathways PLC (CMPS) reports $433 million in cash and advances rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.
LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.
Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.
Annuity payouts are the most competitive they have been in years, which makes the timing of this comparison unusually consequential for anyone sitting on a $675,000 nest egg and trying to decide which structure actually puts more money in their pocket for life.
Johnson & Johnson (JNJ) is back in focus after longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced biopharmaceutical leader Tom Cavanaugh set to succeed her. See our latest analysis for Johnson & Johnson. Johnson & Johnson’s share price has had a strong run in 2026, with a year to date share price return of 22.95% and a 90 day share price return of 13.49%, while the 1 year total shareholder return of 53.04%...
Replacing a six-figure salary with dividends is a math problem first, and the capital requirement swings by more than a million dollars depending on one variable most investors treat as an afterthought.
Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.
Goldman Sachs just handed Microsoft its most coveted endorsement while cutting three other tech giants loose, and the reasoning behind that trade reveals exactly where Wall Street thinks the AI money flows next.
GS, JPM, TRV and JNJ stand out as Dow hits a new high amid an AI-driven tech sell-off, with these blue-chip stocks backed by strong earnings growth.
Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
